TKI Therapy in CML: Practical Considerations
This information was originally presented on September 20, 2013, at the NCCN 8th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Identify the challenges associated with the management of patients with CML
- Summarize the role of mutational analysis, management of side effects, and adherence to TKI therapy
Michael M. Millenson, MD
Fox Chase Cancer Center
- 0.50 Participation
- 0.54 Nurse
- 0.50 Pharmacist
- 0.50 Physician